rEEcur Trial: For Investigators

An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.

Change of Staff

For UK sites: If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. Return both documents to the rEECur Trial Office.

Non-UK sites should contact their National Coordinating Centre for the country specific documents. 

Trial Documents

Links to the current protocol, UK Patient Information Sheet(s), UK Informed Consent Form(s) are provided below. If there has been a recent amendment to the trial please ensure you have R&D approval before using these documents.

For other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc) please contact the rEECur Trial Office.

Non-UK sites should contact their National Coordinating Centre for the country specific documents.

Publications

ASCO (2022) Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) - Abstract

ASCO (2020) Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial - Abstract

ASCO (2020) Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES) - Abstract

ASCO (2019) Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma - Abstract

News and Events

Newsletter (previous editions)

Newsletter Aug-2022 [PDF - 1357KB]

Newsletter Apr-2022 [PDF - 1548KB]

Newsletter Oct-2021 [PDF - 1636KB]

Newsletter Mar-2021 [PDF - 1827KB]

Newsletter Nov-2020 [PDF - 1962KB]

Newsletter Oct-2019 [PDF - 1451KB]

Newsletter Mar-2019 [PDF - 916KB]

Newsletter Sep-2016 [PDF - 359KB]

Newsletter Dec-2015 [PDF - 337KB]

Newsletter Jul-2015 [PDF - 528KB] 

Contact Details

Contact Details

Chief Investigator
Dr Martin McCabe
Consultant Paediatric Oncologist
The Christie Hospital
Manchester
UK

Tel: +44 (0)161 446 3954     or     +44 (0)161 446 3000

Trial Office 
Trial Coordinator:                                            Rebecca Reid
Senior Trial Coordinator:                               Maria Khan   

Trial Monitor:                                                   Davina Scott

Trial Management Team Leader:                 Nicola Fenwick
Trial Statistician:                                              Laura Kirton

Cancer Research UK Clinical Trials Unit (CRCTU)
School of Cancer Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Enquiries
Tel:   +44 (0)121 414 3798
Fax:  +44 (0)121 414 9520
email: rEECur@trials.bham.ac.uk

Trial Entry
Done at site via electronic remote data capture (eRDC)
In the event of system unavailability call the rEECur office.

Tel: 0800 414 3798 (9.00 am till 5.00 pm Monday to Friday)

Serious Adverse Event Reporting
reg@trials.bham.ac.uk

Sponsor
University of Birmingham
Edgbaston
Birmingham
B15 2TT

CRCTU Home Page
http://www.birmingham.ac.uk/research/activity/mds/trials/crctu/index.aspx